1-2-3, spe-cifi-city

Pfizer's axitinib improves PFS vs. Nexavar from Bayer/Onyx in RCC

One byproduct of recent development successes in metastatic renal cell carcinoma has been the emergence of questions about how best to use the various drugs. A variety of head-to-head studies are underway, and the first direct comparison of targeted agents was provided last month by Pfizer Inc., which reported axitinib met the primary endpoint of a Phase III trial, significantly improved progression-free survival vs. Nexavar sorafenib in second-line RCC.

Pfizer did not disclose detailed data on the pan-VEGF receptor tyrosine kinase inhibitor (TKI) because it plans to present the results at a scientific meeting in 1H11.

Glen Andrews, an asset team leader in Pfizer's oncology business unit, told

Read the full 1068 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE